Carregant...
Not All Immune Checkpoints Are Created Equal
Antibodies that block T cell inhibition via the immune checkpoints CTLA-4 and PD-1 have revolutionized cancer therapy during the last 15 years. T cells express additional inhibitory surface receptors that are considered to have potential as targets in cancer immunotherapy. Antibodies against LAG-3 a...
Guardat en:
| Publicat a: | Front Immunol |
|---|---|
| Autors principals: | , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Frontiers Media S.A.
2018
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6127213/ https://ncbi.nlm.nih.gov/pubmed/30233564 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2018.01909 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|